I-Tech AB (ITECH.ST)

SEK 54.5

(-1.8%)

Total Debt Summary of I-Tech AB

  • I-Tech AB's latest annual total debt in 2023 was - SEK , down -100.0% from previous year.
  • I-Tech AB's latest quarterly total debt in 2024 Q1 was - SEK , down 0.0% from previous quarter.
  • I-Tech AB reported annual total debt of 2.25 Million SEK in 2022, down -47.49% from previous year.
  • I-Tech AB reported annual total debt of 4.28 Million SEK in 2021, down -50.24% from previous year.
  • I-Tech AB reported quarterly total debt of - SEK for 2024 Q1, down 0.0% from previous quarter.
  • I-Tech AB reported quarterly total debt of - SEK for 2024 Q2, down 0.0% from previous quarter.

Annual Total Debt Chart of I-Tech AB (2023 - 2015)

Historical Annual Total Debt of I-Tech AB (2023 - 2015)

Year Total Debt Total Debt Growth
2023 - SEK -100.0%
2022 2.25 Million SEK -47.49%
2021 4.28 Million SEK -50.24%
2020 8.61 Million SEK -24.44%
2019 11.4 Million SEK -14.74%
2018 13.37 Million SEK -9.14%
2017 14.72 Million SEK -0.93%
2016 14.86 Million SEK 71.09%
2015 8.68 Million SEK 0.0%

Peer Total Debt Comparison of I-Tech AB

Name Total Debt Total Debt Difference
Alligator Bioscience AB (publ) 16.09 Million SEK 100.0%
Ziccum AB (publ) 857 Thousand SEK 100.0%
Modus Therapeutics Holding AB (publ) - SEK NaN%
BioArctic AB (publ) 4.97 Million SEK 100.0%
Sprint Bioscience AB (publ) - SEK NaN%
Mendus AB (publ) 24.48 Million SEK 100.0%
Genovis AB (publ.) 79.32 Million SEK 100.0%
Intervacc AB (publ) 181 Thousand SEK 100.0%
QuiaPEG Pharmaceuticals Holding AB (publ) 20.61 Million SEK 100.0%
Active Biotech AB (publ) 3 Million SEK 100.0%
Magle Chemoswed Holding AB (publ) 60.3 Million SEK 100.0%
Bio-Works Technologies AB (publ) - SEK NaN%
Aptahem AB (publ) 5 Million SEK 100.0%
Vicore Pharma Holding AB (publ) - SEK NaN%
Kancera AB (publ) - SEK NaN%
Infant Bacterial Therapeutics AB (publ) - SEK NaN%
Fluicell AB (publ) - SEK NaN%
Saniona AB (publ) 71.4 Million SEK 100.0%
Lipigon Pharmaceuticals AB (publ) - SEK NaN%
Biovica International AB (publ) 7.82 Million SEK 100.0%
Spago Nanomedical AB (publ) - SEK NaN%
AcouSort AB (publ) - SEK NaN%
Xintela AB (publ) - SEK NaN%
Abliva AB (publ) 424 Thousand SEK 100.0%
Egetis Therapeutics AB (publ) 108.6 Million SEK 100.0%
Karolinska Development AB (publ) 3.07 Million SEK 100.0%
OncoZenge AB (publ) - SEK NaN%
Amniotics AB (publ) 2.58 Million SEK 100.0%
2cureX AB (publ) - SEK NaN%
CombiGene AB (publ) - SEK NaN%
Asarina Pharma AB (publ) 1 Million SEK 100.0%
Calliditas Therapeutics AB (publ) 979.13 Million SEK 100.0%
Camurus AB (publ) 24.5 Million SEK 100.0%
Corline Biomedical AB - SEK NaN%
IRLAB Therapeutics AB (publ) 27.56 Million SEK 100.0%
Isofol Medical AB (publ) - SEK NaN%
Hansa Biopharma AB (publ) 866.76 Million SEK 100.0%
Cyxone AB (publ) 858 Thousand SEK 100.0%
ExpreS2ion Biotech Holding AB (publ) 1.71 Million SEK 100.0%
Biosergen AB - SEK NaN%
Cantargia AB (publ) - SEK NaN%
NextCell Pharma AB - SEK NaN%
Xspray Pharma AB (publ) 36.8 Million SEK 100.0%
Elicera Therapeutics AB (publ) - SEK NaN%
Nanologica AB (publ) 666 Thousand SEK 100.0%
SynAct Pharma AB 637 Thousand SEK 100.0%
Annexin Pharmaceuticals AB (publ) - SEK NaN%
Stayble Therapeutics AB (publ) 850 Thousand SEK 100.0%
LIDDS AB (publ) - SEK NaN%
Lipum AB (publ) 1.76 Million SEK 100.0%
BioInvent International AB (publ) 23.24 Million SEK 100.0%
Alzinova AB (publ) 800 Thousand SEK 100.0%
Oncopeptides AB (publ) 106.48 Million SEK 100.0%
Pila Pharma AB (publ) 773.08 Thousand SEK 100.0%
Guard Therapeutics International AB (publ) - SEK NaN%
Scandinavian ChemoTech AB (publ) - SEK NaN%
Simris Alg AB (publ) 90.74 Million SEK 100.0%
Diamyd Medical AB (publ) 30.67 Million SEK 100.0%
Xbrane Biopharma AB (publ) 231.47 Million SEK 100.0%
Ascelia Pharma AB (publ) 1.06 Million SEK 100.0%
Diagonal Bio AB (publ) - SEK NaN%